Induced Pluripotent Stem Cell Core
The Induced Pluripotent Stem Cell (iPSC) Core (David and Janet Polak Foundation Stem Cell Core Laboratory) at the Board of Governors Regenerative Medicine Institute uses the latest techniques to reprogram, expand and characterize human iPS cells from human skin or blood tissues of healthy subjects and diseased patients.
We then turn the iPS cells into specific cells of the human body, including components of the nervous system, eyes, blood, bones, heart, gut, liver and pancreas, for use by researchers. Some applications of this technology include human “disease modeling-in-a-dish,” developing human reporter cell lines via genetic modification, drug screening on pathological human cell types and potentially developing cell replacement or regenerative therapies.
The IPSC Core is involved in many projects including:
NIH LINCS Program
By generating and making public data that indicates how cells respond to various genetic and environmental stressors, the LINCS project will help us gain a more detailed understanding of cell pathways and aid efforts to develop therapies that might restore perturbed pathways and networks to their normal states. The LINCS website is a source of information for the research community and general public about the LINCS project. This website along with the LINCS Data Portal contains details about the assays, cell types and perturbagens that are currently part of the library, as well as links to participating sites, data releases from the sites and software that can be used for analyzing the data.
Lothian Birth Cohort
The neurobiology of cognitive ability and its decline during ageing are poorly understood. Human iPSC lines from the Lothian Birth Cohort 1936 comprise individuals with rich life-course cognitive performance data (Taylor et al., 2018, Wardlaw et al., 2011), affording a rare model to investigate molecular mechanisms relevant to differences in brain development, cellular resilience, and vulnerability to pathology.
Browse Cell Line Catalog
Hundreds of already established lines spanning over 30 degenerative diseases.